Beijing Aitapu Biopharmaceutical

Beijing Aitapu Biopharmaceutical is a clinical-stage biotechnology company based in Beijing, China, focused on the discovery and development of innovative small molecule targeted therapies for oncology. The company utilizes a proprietary structure-based drug design platform to address unmet medical needs, particularly focusing on overcoming resistance to existing cancer treatments. Its lead candidate, ATP-001, is a fourth-generation EGFR inhibitor designed to target the C797S mutation in non-small cell lung cancer. Additionally, the company is advancing a pipeline of preclinical assets targeting other key oncogenic drivers such as KRAS. Aitapu is backed by prominent venture capital firms including Sequoia China and Matrix Partners China. The company aims to provide more effective and precise treatment options for cancer patients globally.